Steve Harr, Sana CEO

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

A uni­corn mul­ti­ple times over, Sana Biotech­nol­o­gy hit Nas­daq run­ning in Feb­ru­ary with its next-gen cell ther­a­pies still months away from the clin­ic. Now, Sana …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.